Mersana

FDA pauses Mersana’s clinical trial after patient dies
FDA pauses Mersana’s clinical trial after patient dies
Endpoints
Mersana
clinical trials
FDA
patient death
cancer
XMT-2056
antibody-drug conjugate
Flag link:
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
Flag link:
GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep
GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep
Fierce Biotech
GSK
Mersana
antibody-drug conjugate
Blenrep
XMT-2056
Flag link:
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets
Fierce Biotech
JNJ
Janssen
Mersana
antibody-drug conjugate
biobucks
Flag link:
Mersana starts to lose its shine
Mersana starts to lose its shine
EP Vantage
Mersana
ovarian cancer
XMT-1536
antibody-drug conjugate
Flag link:
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
BioSpace
JPMHC 2019
SAGE Therapeutics
SAGE-217
Mersana
Novavax
Denali Therapeutics
AstraZeneca
Amarin
FDA
government shutdown
Flag link:
FDA lifts clinical hold from Mersana’s breast cancer trial
FDA lifts clinical hold from Mersana’s breast cancer trial
Fierce Biotech
FDA
clinical trials
Mersana
antibody-drug conjugate
XMT-1522
breast cancer
Flag link:
Patient death prompts FDA hold on Mersana’s lead cancer ADC
Patient death prompts FDA hold on Mersana’s lead cancer ADC
Fierce Biotech
Mersana
XMT-1522
antibody-drug conjugate
patient deaths
clinical trials
Flag link:
After billion-dollar drug deal, patient death and trial hold cripple Mersana’s shares
After billion-dollar drug deal, patient death and trial hold cripple Mersana’s shares
Endpoints
Mersana
patient deaths
XMT-1522
Flag link:
Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul
Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul
Endpoints
IPOs
biotech
Dova Pharmaceuticals
Mersana
Aileron
Flag link:
Teva licenses Mersana cancer treatment for $334M
Teva licenses Mersana cancer treatment for $334M
Yahoo/AP
Teva Pharmaceuticals
Mersana
cancer
liscensing
Flag link: